Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer

Matthias Moll; Piero Fossati; Carola Lütgendorf-Caucig; Eugen Hug

doi:10.1097/MOU.0000000000001327

Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer

Matthias Moll^*, Piero Fossati, Carola Lütgendorf-Caucig, Eugen Hug

^*Corresponding author for this work

Department of Radiation Oncology with an emphasis on Particle Therapy

Research output: Journal article (peer-reviewed) › Review article

1 Citation (Scopus)

Abstract

PURPOSE OF REVIEW: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.

RECENT FINDINGS: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.

SUMMARY: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.

Original language	English
Pages (from-to)	568-573
Number of pages	6
Journal	Current Opinion in Urology
Volume	35
Issue number	5
DOIs	https://doi.org/10.1097/MOU.0000000000001327
Publication status	Published - 01 Sept 2025

Keywords

Humans
Prostatic Neoplasms/radiotherapy
Male
Heavy Ion Radiotherapy/methods
Radiotherapy Dosage
Treatment Outcome
Risk Factors
Risk Assessment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MOU.0000000000001327

Cite this

@article{25110fd6ffef4a34bcffacc695ecea0c,

title = "Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer",

abstract = "PURPOSE OF REVIEW: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.RECENT FINDINGS: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.SUMMARY: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.",

keywords = "Humans, Prostatic Neoplasms/radiotherapy, Male, Heavy Ion Radiotherapy/methods, Radiotherapy Dosage, Treatment Outcome, Risk Factors, Risk Assessment",

author = "Matthias Moll and Piero Fossati and Carola L{\"u}tgendorf-Caucig and Eugen Hug",

year = "2025",

month = sep,

day = "1",

doi = "10.1097/MOU.0000000000001327",

language = "English",

volume = "35",

pages = "568--573",

journal = "Current Opinion in Urology",

issn = "0963-0643",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer

AU - Moll, Matthias

AU - Fossati, Piero

AU - Lütgendorf-Caucig, Carola

AU - Hug, Eugen

PY - 2025/9/1

Y1 - 2025/9/1

N2 - PURPOSE OF REVIEW: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.RECENT FINDINGS: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.SUMMARY: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.

AB - PURPOSE OF REVIEW: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.RECENT FINDINGS: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.SUMMARY: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.

KW - Humans

KW - Prostatic Neoplasms/radiotherapy

KW - Male

KW - Heavy Ion Radiotherapy/methods

KW - Radiotherapy Dosage

KW - Treatment Outcome

KW - Risk Factors

KW - Risk Assessment

UR - https://www.scopus.com/pages/publications/105011363128

U2 - 10.1097/MOU.0000000000001327

DO - 10.1097/MOU.0000000000001327

M3 - Review article

C2 - 40765430

SN - 0963-0643

VL - 35

SP - 568

EP - 573

JO - Current Opinion in Urology

JF - Current Opinion in Urology

IS - 5

ER -

Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this